Rosario, Santa Fe – Faced with dwindling national support for critical cancer treatments, the province of Santa Fe is bolstering its own healthcare system to ensure residents continue to receive the medications they need. The move comes as Argentina grapples with economic challenges impacting the availability of essential medical supplies, and highlights a growing tension between provincial autonomy and national healthcare provision. The province has seen a significant increase in healthcare utilization in recent years, with patient visits rising from 9,160,361 in 2021 to a projected 13,588,776 in 2025, serving over 1.8 million people annually.
The situation is particularly acute regarding access to oncology drugs. Provincial Health Minister Silvia Ciancio has publicly stated that the national government is experiencing “delays, discontinuations, adjustments, and cuts” in funding for vital areas including cancer care, transplant medications, and sexual health supplies. This has forced Santa Fe to take proactive steps to safeguard patient care, particularly as the national Banco de Drogas Especiales (National Special Drugs Bank) struggles to meet provincial demands.
A Growing Gap in Cancer Treatment Access
Data presented by Minister Ciancio reveals a stark decline in the reliability of national drug supplies. In 2025, 63% of requested cancer treatments through the national bank were either not fulfilled or arrived incompletely – a dramatic increase from 37% in 2024. Specifically, 2,525 out of 3,990 treatment requests went unmet this year, compared to 1,372 out of 3,771 in 2024. In other words that thousands of patients in Santa Fe are facing uncertainty in receiving the medications crucial to their treatment plans. “For every denial or delay, there is a patient not receiving the medication they need,” Ciancio emphasized.
The province’s response has been a strategic shift towards centralized purchasing. Governor Maximiliano Pullaro spearheaded a plan to directly procure essential medications, circumventing the increasingly unreliable national supply chain. “If we hadn’t moved forward with this purchasing strategy…we wouldn’t be able to guarantee the provision of medications today,” Ciancio stated. This approach aims to ensure that residents of Santa Fe have access to the care they require, regardless of national-level constraints.
Strategic Purchasing and Cost Savings
Santa Fe’s centralized purchasing policy, implemented in 2024, has proven to be a cost-effective solution. In 2025, the province acquired 62 pharmaceutical products for oncology treatments for $951,733,085 (approximately $2.5 million USD as of November 22, 2023 – XE.com), realizing a 92% savings compared to public retail prices. This substantial cost reduction has allowed the province to expand coverage and treat more patients with the same resources.
Building on this success, a further purchase of 44 oncology medications is currently underway, with a budget of $2,024,331,583.40 (approximately $5.3 million USD as of November 22, 2023 – XE.com). The bidding process involved 15 potential suppliers and is now in the technical analysis phase before final adjudication. The province anticipates this procurement will further stabilize the supply of essential cancer drugs.
The province’s proactive approach isn’t limited to oncology. Ciancio noted that national-level disruptions extend to medications for transplant patients, high-cost drugs for rare diseases, and even basic sexual health supplies, underscoring a systemic challenge within Argentina’s healthcare infrastructure. The situation highlights the increasing financial strain on the national healthcare system and the growing need for provincial-level solutions.
The increased demand on Santa Fe’s public health system is also reflected in the rising number of patient interactions. The province’s healthcare network has expanded its reach, providing care to a growing population. This expansion, coupled with the national supply issues, has necessitated a significant investment in provincial healthcare infrastructure and procurement strategies.
While Santa Fe’s efforts offer a model for other provinces facing similar challenges, the long-term sustainability of this approach remains dependent on the overall economic stability of Argentina and the future policies of the national government. The province is actively monitoring the situation and preparing for potential further disruptions in national supply chains.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next key step will be the completion of the current procurement process for the 44 oncology medications, with adjudication expected in the coming weeks. The province will continue to monitor national supply levels and adapt its strategies as needed to ensure uninterrupted access to essential cancer treatments for its residents. We encourage readers to share their thoughts and experiences with healthcare access in Argentina in the comments below.
